| Name | Title | Contact Details |
|---|
The Accreditation Council for Graduate Medical Education (ACGME) is a private, non-profit, professional organization responsible for the accreditation of approximately 10,000 residency and fellowship programs and the approximately 800 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 125,000 resident and fellow physicians in 150 specialties and subspecialties. The ACGME`s mission is to improve health care and population health by assessing and advancing the quality of resident physicians` education through accreditation. We imagine a world characterized by: • A structured approach to evaluating the competency of all residents and fellows, • Motivated physician role models leading all graduate medical education programs, • High-quality, supervised, humanistic, clinical educational experience, with customized formative feedback, • Clinical learning environments characterized by excellence in clinical care, safety, and professionalism, • Residents and fellows achieving specialty specific proficiency prior to graduation, • Residents and fellows prepared to become Virtuous Physicians who place the needs and well-being of patients first.
White Oak Manor-Shelby is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthLink Innovations is a company that provides personalized home health care solutions to improve the patient and their familys quality of life.
Spryance Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.